Navigation Links
NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
Date:10/21/2009

SOUTH SAN FRANCISCO, Calif., Oct. 21 /PRNewswire/ -- NGM Biopharmaceuticals, Inc. (NGM), a private company dedicated to the discovery and development of novel biotherapeutics for the treatment of Type 2 diabetes and other metabolic diseases, today announced that Arthur D. Levinson, Ph.D., the Chairman of Genentech's Board of Directors, has been appointed to NGM's Board of Directors. Under Dr. Levinson's leadership as Chairman and Chief Executive Officer from 1995 to 2009, Genentech became a leading global therapeutics company that was widely recognized as the most innovative biotechnology company in the industry.

Founded in 2008, NGM has created a proprietary discovery platform and pipeline based on biological insights into the relationship between bariatric gastric bypass surgery and post-surgical resolution of Type 2 diabetes and other metabolic disorders. Dr. Levinson will join other distinguished advisors in guiding the Company's research, development and business strategies.

"NGM has the attributes and values that I believe are fundamental to building an innovative and sustainable biotechnology company," said Dr. Levinson. "The company's creative approach to scientific research should provide new insights into disease processes, and support the discovery of differentiated, clinically important medicines."

"Art's accomplishments and leadership during his thirty years at Genentech are legendary," said David V. Goeddel, Ph.D., NGM's Chairman and Chief Executive Officer. "His scientific and business acumen will be invaluable in shaping NGM's continued progress."

Dr. Levinson is currently the chairman of Genentech's Board of Directors, an advisor to Genentech's Research and Early Development center and a member of Roche's Scientific Resource Board. In addition, he will be nominated to the Board of Directors of Roche Holding Ltd. in March 2010. Among his significant commitments are his memberships on the Board of Directors of the Broad Institute of the Massachusetts Institute of Technology and the Board of Scientific Consultants of Memorial Sloan-Kettering Cancer Center.

Dr. Levinson is the recipient of numerous awards and honors, including the Irvington Institute's 1999 Corporate Leadership Award in Science, the National Breast Cancer Coalition's Corporate Leadership Award, Institutional Investor's Best Biotech CEO award, Princeton University's James Madison Medal for a distinguished career in scientific research and in biotechnology, Barron's designation as one of "The World's Most Respected CEOs" and the Best Practice Institute's "25 Top CEOs." Dr. Levinson also serves on the board of directors of Apple Inc.

About NGM Biopharmaceuticals

NGM Biopharmaceuticals, Inc. is a privately held drug discovery and development company dedicated to developing transformational medicines that significantly improve human health. NGM has devised a novel discovery platform, relying on human clinical and genetic observations, to identify and validate targets that impact the underlying etiology of disease. The Company's strategy is to focus on mining the complex biological interactions within the neuroendocrine gastrointestinal environment to elucidate the roles of previously unidentified or unexplored hormones, receptors and other metabolic factors that are involved in the systemic regulation of glucose homeostasis and that play causative roles in diseases.

NGM is generating a rich pipeline of new targets that the Company is using to develop novel treatments for metabolic diseases, such as obesity, muscle wasting and cardiovascular disease in addition to diabetes. Founded in 2008, NGM has world-class scientists and an accomplished executive team with broad experience in building and managing biotechnology companies. NGM is headquartered in South San Francisco, California. For more information, please visit the Company's website at http://www.ngmbio.com.

SOURCE NGM Biopharmaceuticals, Inc.


'/>"/>
SOURCE NGM Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
2. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
7. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
8. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
9. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... WARSAW, Ind. , Feb. 5, 2016  Zimmer ... the pricing of the previously announced underwritten secondary offering ... of its stockholders, consisting of affiliates of Blackstone and ... public at an initial price of $96.45 per share. ... of the offering.  Neither Zimmer Biomet nor any of ...
(Date:2/5/2016)... France , Germany , Italy ... ). It includes a 10-year epidemiology forecast for the total prevalent ... sex in these markets. GD epidemiology report is written and developed by ... and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... Feb. 4, 2016  The Senior Care Pharmacy ... Reform Committee Chairman Jason Chaffetz (R-UT) ... today,s hearing , "Developments in the Prescription ... and growing questions about abusive pharmacy benefit manager ... (R-UT) and Ranking Member Elijah Cummings (D-MD) are ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute Valentine’s Day ... tips of your toes. Foot massage, whether administered by a professional masseuse or a ... The American Board of Multiple Specialties in Podiatry (ABMSP) has taken the ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... from across the country gathered at the La Valencia Hotel in San Diego, ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with the ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot ... 2015 Best in KLAS: Software & Services for HIT Implementation Support & Staffing ... report independently ranks vendor performance by healthcare executives, managers and clinicians representing over ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is a ... drop zone to the next using Colorize's dynamic moving camera. Colorize is perfect for ... includes a 3D slideshow environment with 1 to 5 focus points per scene, stage ...
(Date:2/5/2016)... ... , ... Calls Blacklist has just been updated by mobile app developer Vlad ... has fixed known bugs within the app. Calls Blacklist allows its users to only ... any of their device’s battery power or memory. It provides a powerful call blocker ...
Breaking Medicine News(10 mins):